Loading…
← CockpitCompetitor Analysis › 226950.KS OliX Pharmaceuticals, Inc.Open in the cockpit ↗

OliX Pharmaceuticals, Inc.226950.KSCompetitor analysis, valuation and peers

South Korea · KRW·Health Care›Pharmaceuticals: Major

Korean biotech developing an RNAi (siRNA) therapeutics platform, licensing candidates for eye, skin and other diseases to global partners.

Momentum weak 23
Mkt cap
$1.35B
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$12.2M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-79.0 pp
WACC 6.1%
Hurdle
n/a
no reverse DCF
Close · KRW₩78,500
1D+0.1%
1W-5.4%
1M-19.6%
3M-29.9%
6M-51.1%
YTD-44.1%
1Y-32.6%
ATR %10.4%
52w lowhigh63.8% off high

What OliX Pharmaceuticals does

Korean biotech developing an RNAi (siRNA) therapeutics platform, licensing candidates for eye, skin and other diseases to global partners.

No product sales; income is licence payments, such as an upfront fee when a partner signs and milestones if its programmes progress, so revenue is irregular and depends on partners. It develops drugs through early stages and typically relies on partners for the later, costlier ones.

Products and services

  • siRNA drug-development platform
  • Ophthalmology/dermatology RNAi candidates

Customers

  • Global pharma licensing partners

Where it sits in the supply chain

  • Biotechnology
  • RNAi (siRNA) drug platform
  • Global pharma licensing

What could go right

  • New global licensing deals
  • Clinical progress on lead candidates

What could go wrong

  • Clinical-trial failure risk
  • Early-stage pipeline concentration

Moat: narrow (IP / patents). Proprietary asymmetric siRNA (cp-asiRNA) platform, a differentiated RNAi drug-design approach.

Headquarters: Suwon, South Korea · Founded: 2010 · Employees: 76

Named competitors

OliX Pharmaceuticals at a glance

Size OliX Pharmaceuticals (226950.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.35B, the 191st largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩78,500 on 18 Nov 2026.

Performance Over six months the shares fell 51.1%, against -14.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 20 in its peer set.

Growth Revenue grew 26.6% over the last twelve months (peer median +10.1%); the operating margin is -384.5% (peer median 11.3%).

Valuation It trades at 125.0× enterprise value to sales against a peer median of 3.8× (4th most expensive of 18).

Capital Return on invested capital runs 79.0 points below its cost of capital (6.1% WACC).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 88226950.KS 47
Six months, rebased to 100: OliX Pharmaceuticals against the median of its 20 peers (local-currency closes).

OliX Pharmaceuticals financials

Reported figures in KRW; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₩12.9B₩14.7B₩5.68B₩17.1B₩9.32B
Revenue growth—+158%-67%+83%—
Gross profit₩10.6B₩12.2B₩3.05B₩14.4B₩7.35B
EBITDA-₩47.2B-₩27.5B-₩28.3B-₩15.5B-₩20.4B
Net income-₩17.5B-₩15.7B-₩40.7B-₩19.1B-₩19.5B
Free cash flow-₩48.7B-₩17.2B-₩42.1B-₩29.9B-₩32.9B
Capital expenditure₩1.92B₩1.86B₩14.1B₩8.96B₩2.53B
Total debt₩20.7B₩23.3B₩39.2B₩39.4B₩44.0B

Quarterly statements and history in the cockpit →

OliX Pharmaceuticals competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%NANO300181002099068760002020688293MNKDINVAOCULLBRX301263DMRAMARKSANS310210140410002332PAHCAMPH226950.KS6-month return →1-month return →
Up and to the right = strong over both horizons. OliX Pharmaceuticals is the large dot.

Fundamentals: revenue growth against valuation

-100%0%+100%0×25,000×50,000×75,000×NANO300181002099688293OCUL310210226950.KSRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. OliX Pharmaceuticals is the large dot.

OliX Pharmaceuticals competitors and peer comparison

Head to head with its named competitors (226950.KS vs ALNY)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
OliX Pharmaceuticals 226950.KS$1.35B-51%+27%-384%125.0×n/a
Alnylam Pharmaceuticals ALNY$20.0B-50%+56%20%3.9×0.5%

How OliX Pharmaceuticals compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

OliX Pharmaceuticals against its 20 peers (data as of 18 Nov 2026)
Measure226950.KSPeer medianRank in peer set
1-month return-19.6%-1.8%2nd lowest of 20
6-month return-51.1%-14.6%2nd lowest of 20
Distance from 52-week high-63.8%-40.0%4th lowest of 20
Revenue growth (TTM)+26.6%+10.1%3rd highest of 18
Operating margin-384.5%11.3%4th lowest of 18
EV / Sales125.0×3.8×4th most expensive of 18
ROIC minus cost of capital-79.0 pp-0.5 pp4th lowest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%125.0×n/an/a
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%146.3×n/an/a
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%3.0×3.9%+22.8%
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%4.7×n/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%3.0×10.2%+18.1%
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%2.1×-9.6%+4.6%
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%9.6×25.9%+23.1%
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
MannKind MNKDUnited States$1.31B+25%+32%-2%4.0×n/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%2.2×-17.2%+3.9%
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%17.0×n/an/a
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%12.8×n/an/a
Damora Therapeutics DMRAUnited States$1.42B-5%n/an/an/an/an/a
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%0.8×-18.1%+7.0%
Marksans Pharma MARKSANS.NSIndia$1.43B+36%+24%20%3.8×31.0%+16.6%
Voronoi 310210.KSSouth Korea$1.43B-62%-100%-438,152%85,633.6×n/an/a
Mezzion Pharma 140410.KSSouth Korea$1.43B-15%+13%-211%216.0×n/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%2.0×-0.4%-1.3%
Phibro Animal Health PAHCUnited States$1.44B+5%+10%13%1.4×-6.4%+12.7%
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%2.3×2.5%+15.5%

Questions

Who are OliX Pharmaceuticals's main competitors?
Named competitors: Alnylam Pharmaceuticals (ALNY). The cockpit's measured peer set (industry) also includes Nanobiotix (NANO.PA), Zhejiang Jolly Pharmaceutical (300181.SZ), Zhejiang Hisoar Pharmaceutical (002099.SZ), Celltrion Pharm (068760.KS), Zhejiang Jingxin Pharmaceutical (002020.SZ), Shanghai OPM Biosciences (688293.SS).
Is OliX Pharmaceuticals expensive compared with its peers?
On ev / sales it trades at 125.0× against a peer median of 3.8×, 4th most expensive of 18 in its peer set.
How has OliX Pharmaceuticals stock performed?
Over six months to 18 Nov 2026 the shares returned -51.1% against -14.6% for the median peer; over one year -32.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.